



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/516,613	12/03/2004	Paolo Alberto Veronesi	IPU1954-008	7113
8698	7590	06/27/2007		
STANDLEY LAW GROUP LLP 495 METRO PLACE SOUTH SUITE 210 DUBLIN, OH 43017			EXAMINER AUDET, MAURY A	
			ART UNIT	PAPER NUMBER
			1654	
			MAIL DATE	DELIVERY MODE
			06/27/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	Application No. 10/516,613	Applicant(s) VERONESI ET AL.	
	Examiner Maury Audet	Art Unit 1654	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 31 May 2005.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 2-41 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 2-41 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some    c) ☒ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date <u>05/05, 12/04</u> . | 6) <input type="checkbox"/> Other: _____  |

Art Unit: 1654

### DETAILED ACTION

The present application has been transferred from Examiner Harle to the present Examiner. Amended claims 2-41 are examined on the merits. There are 5 independent claims: 26-28 to products (compositions comprising THAM and any nasal peptide) and claims 34-35 to the methods of using the same compositions for nasal administration.

#### *Priority*

Acknowledgment is made of applicant's claim for foreign priority based on an application filed in Italy on 07/29/02. It is noted, however, that applicant has not filed a certified copy of the MI2002A 001684 application as required by 35 U.S.C. 119(b).

#### *Claim Rejections - 35 USC § 112 1<sup>st</sup> New Matter*

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 11-12, 26, 30-31, and 32-34 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed (National Stage 12/3/04), had possession of the claimed invention. Namely, an amendment was filed on 5/31/05, to the amount THAM to "above 4.0 mg/ml to 30 mg/ml" or further subspecies ranges therein.

Art Unit: 1654

No support is found in the originally filed application for parsing out this subspecies of the originally filed, broad genus range of THAM (any effective amount or 0.5 mg/ml to 30 mg/ml).

***Claim Rejections - 35 USC § 112 1<sup>st</sup> Written Description***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 2-41 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

*Vas-Cath Inc. V. Mahurka*, 19 USPQ2d 1111, states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention, for purposes of the “written description” inquiry, is *whatever is now claimed*” (see page 1117).

A review of the language of the claim indicates that these claims are drawn to a genus, i.e., *any nasal peptide fragment*.

A description of a genus may be achieved by means of a recitation of a representative number of species falling within the scope of the genus or of a recitation of structural features common to the members of the genus, which features constitute a substantial portion of the genus. *Regents of the University of California v. Eli Lilly & Co.*, 119 F3d 1559, 1569, 43

Art Unit: 1654

USPQ2d 1398, 1406 (Fed. Cir. 1997). In *Regents of the University of California v. Eli Lilly* (43 USPQ2d 1398-1412), the court held that a generic statement which defines a genus of nucleic acids by only their functional activity does not provide an adequate written description of the genus. The court indicated that, while applicants are not required to disclose every species encompassed by a genus, the description of the genus is achieved by the recitation of a representative number of species falling within the scope of the claimed genus. At section B(1), the court states “An adequate written description of a DNA ... requires a precise definition, such as by structure, formula, chemical name, or physical properties, not a mere wish or plan for obtaining the claimed chemical invention”.

There is NOT a single species of the claimed genus disclosed that is within the scope of the claimed genus, *i.e. any nasal peptide fragment*. There is substantial variability among the species which do not permit the mere statement aforementioned as a substitute for the description of these specific fragments.

One of skill in the art would not recognize from the disclosure that the applicant was in possession of the genus of which comprises any nasal peptide fragment. The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed” (see *Vas-Cath* at page 1116).

### ***Invention***

Applicant's invention is to compositions comprising THAM (also known as [tris(hydroxymethyl)aminomethane] or TRIS or tromethamine) with any nasally administrable peptide (and other random additives commonly used in like-kind compositions); or methods of using the same for nasal administration. The European International Authority cited 3 “X”

Art Unit: 1654

references (EP 0726075A; WO0152937 (now US 6,434,162); and IT 1243742) as expressly teaching all originally filed 24 claims. It is noted that Applicant has since amended the claims (the Examiner finds only as to the amount of THAM administered), in an attempt to get around 1 or more of these references cited by the International Authority. The amount of THAM originally filed throughout claims was any amount or any amount between 0.5 mg/ml to 30 mg/ml. The amount of THAM now amended claimed into e.g. claims 11-12, 26, 30-31, and 32-34 is "above 4.0 mg/ml to 30 mg/ml" or ranges therein.

It is noted that Applicant's use of the modifier "depolarizing" nasal epithelial cells is merely an inherent physiological property/effect of any composition comprising THAM and a peptide which is or can be administered via the nasal route.

### ***Claim Rejections - 35 USC § 102/103***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1654

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 2-41 rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Veronesi et al. (EP 0726075A).

Veronesi et al. teach a nasally administered composition comprising a nasal peptide (calcitonin) and THAM. Wherein THAM may be administered at from 1.0 to 4.0 mg/ml, as well as the other components of the present invention (entire document, especially abstract, page 2, lines 3-4, claims 1, 4, 5, 7, 8, 11, 15, 16, 23 and Examples 1 and 2). Veronesi et al. does not expressly teach THAM administration of "above 4.0 mg/ml to 30 mg/ml".

As to the 103 side of the amount of THAM/TRIS/tromethamine administration, it would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to use any known amount of this agent in Veronesi et al. (Applicant's earlier work), because neither Applicants earlier work nor Applicant's the present application - which originally filed claims to any amount of THAM or preferably from 0.5 mg/ml to 30 mg/ml - recite any unexpected result from any amount/range of THAM, thus any known range/amount is deemed to carry out the same effect, absent credible evidence to the contrary. Furthermore, it is noted that another of the cited references (now US 6,434,162) by the same International Authority discussed above, recites the use of about 1.5 mg/ml to about 4.5 mg/ml - e.g. "above 4.0 mg/ml".

Art Unit: 1654

– e.g. “above 4.0 mg/ml”. So even if Applicant does overcome the New Matter Rejection and 102 rejection, it would have been obvious to one of ordinary skill in the art to use THAM at “above 4.0 mg/ml” for the same purpose/composition].

From the teachings of the reference(s), it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention.

Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

### ***Conclusion***

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maury Audet whose telephone number is 571-272-0960. The examiner can normally be reached on M-Th. 7AM-5:30PM (10 Hrs.).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.



Art Unit: 1654

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MA, 06/23/2007



MAURY ADET  
PATENT EXAMINER